AR050194A1 - Analogos de biaril piperazinil-piridina sustituidos - Google Patents
Analogos de biaril piperazinil-piridina sustituidosInfo
- Publication number
- AR050194A1 AR050194A1 ARP050103213A ARP050103213A AR050194A1 AR 050194 A1 AR050194 A1 AR 050194A1 AR P050103213 A ARP050103213 A AR P050103213A AR P050103213 A ARP050103213 A AR P050103213A AR 050194 A1 AR050194 A1 AR 050194A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- mono
- independently selected
- halogen
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Tales compuestos son ligantes que pueden utilizarse para modular la actividad de un receptor específico in vivo o in vitro, y que son particularmente utiles en el tratamiento de cuadros asociados con la activacion patologica de los receptores en seres humanos, animales domésticos y ganado. También se proporcionan las composiciones farmacéuticas y los métodos para usar dichos compuestos en el tratamiento de esos desordenes, así como métodos para usar dichos ligantes para estudios de localizacion de receptores. Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptables del mismo, en donde: Ar2 es fenilo o un heterociclo aromático de 6 miembros, cada uno de los cuales está sustituido con desde 0 a 4 sustituyentes independientemente elegidos de R2; X, Y y Z son independientemente CRx o N, de tal modo que por lo menos uno de X, Y y Z es N; D, K, J y F son independientemente N, CH o carbono sustituido con un sustituyente representado por R1 o R10; Rx es elegido independientemente en cada caso entre hidrogeno, halogeno, alquilo C1-4, amino, ciano y mono- o di-(alquilC1-4)amino; R1 representa desde 0 a 3 sustituyentes elegidos independientemente entre: a) halogeno, ciano y nitro; b) grupos de la formula -Q-M-Ry; y c) grupos que se toman en forma conjunta con R10 para formar un anillo heterocíclico o carbocíclico de 5 a 7 miembros fusionados que está sustituido con desde 0 a 4 sustituyentes elegidos independientemente entre halogeno, ciano, nitro y grupos de la formula -Q-M-Ry; R10 representa un sustituyente elegido entre: a) grupos de la formula -Q-M-Ry; y b) grupos que se toman en forma conjunta con un R1 para formar un anillo heterocíclico o carbocíclico de 5 a 7 miembros opcionalmente sustituidos, fusionados; de tal modo que R10 no es hidroxi, amino ni un grupo no sustituido elegido entre: alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquilC2-6éter, alcanoilo C2-6, alcanona C3-6, haloalquilo C1-6, haloalcoxi C1-6, mono- o di-(alquil C1-6)amino, alquilC1-6-sulfonilo, mono- o di-(alquil C1-6)aminosulfonilo o mono- o di-(alquil C1-6)aminocarbonilo; cada Q es independientemente elegido entre alquileno C0-4; cada M está independientemente ausente o seleccionado entre 0, C(=O), OC(=O), C(=O)O, O-C(=O)O, S(O)m, N(Rz), C(=O)N(Rz), C(=NH)N(Rz), N(Rz)C(=O), N(Rz)C(=NH), N(Rz)S(O)m, S(O)mN(Rz) y N[S(O)mN(Rz)]S(O)m; en donde m es independientemente seleccionado en cada caso entre 0, 1 y 2; y Rz es independientemente seleccionado en cada caso entre hidrogeno, alquilo C1-8 y grupos que se toman junto con Ry para formar un heterociclo de 4 a 7 miembros opcionalmente sustituido; y cada Ry es independientemente hidrogeno, haloalquilo C1-8, alquilo C1-8, carbocicloC3-8alquiloC0-4, heterociclo de 4 a 7 miembros)alquiloC0-4, o se toma en forma conjunta con Rz para formar un heterociclo de 4 a 7 miembros en donde cada alquilo, carbociclo y heterociclo está sustituido con desde 0 a 4 sustituyentes independientemente seleccionados entre hidroxi, halogeno, amino, ciano, nitro, oxo, -COOH, aminocarbonilo, aminosulfonilo, alquilo C1-6, cicloalquilo C3-7, alquiloC2-6éter, alcanoilo C1-6, alquilC1-6-sulfonilo, alcoxi C1-8, alquiltio C1-8, mono- y di-(alquil C1-6)aminocarbonilo, mono- y di-(alquil C1-6)aminosulfonilo, mono- y di(alquil C1-6)amino y fenilo; de tal modo que Ry no es hidrogeno si Q es alquilo C0 y si M está ausente; cada R2 es: a) independientemente elegido entre i) hidroxi, amino, ciano, halogeno, -COOH, aminosulfonilo, nitro y aminocarbonilo; y ii) alquilo C1-6, cicloalquilC3-8alquiloC0-4, haloalquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquilC2-6éter, alcanoilo C2-6, alcoxiC1-6-carbonilo, alcanoiloxi C2-6, alcanona C3- 6, mono- y di-(alquil C1-6)aminoalquilC0-6, (heterociclo de 4 a 7 miembros)alquiloC0-4, alquilC1-6-sulfonilo, mono- y di-(alquil C1-6)aminosulfonilo, y mono- y di-(alquil C1-6)aminocarbonilo, cada uno de los cuales está sustituido con desde 0 a 4 sustituyentes independientemente elegidos entre halogeno, hidroxi, ciano, amino, aminocarbonilo, aminosulfonilo, -COOH y oxo; o b) tomado junto con un R2 adyacente para formar un grupo heterocíclico o carbocíclico de 5 a 13 miembros fusionados que está sustituido con desde 0 a 3 sustituyentes independientemente elegidos entre halogeno, oxo y alquilo C1-6; R3 está seleccionado entre: i) hidrogeno y halogeno; ii) alquilo C1-6, cicloalquilC3-8alquiloC0-2, haloalquilo C1-6 y fenialquilo C0-2; y iii) grupos de la formula (2), en donde: L es alquileno C0-6 o alquileno C1-6 que está tomado junto con R5, R6 o R7 para formar un heterociclo de 4 a 7 miembros; W es O, CO, S, SO o SO2; R5 y R6 están: a) independientemente elegidos entre hidrogeno, alquilo C1-12, alquenilo C2-12, cicloalquilC3-8alquiloC0-4, alcanoilo C2-6, alquilC1-6-sulfonilo, fenilalquilo C0-6, (heterociclo de 4 a 7 miembros)alquiloC0-6 y grupos que están unidos a L para formar un heterociclo de 4 a 7 miembros; o b) unidos para formar un heterociclo de 4 a 12 miembros; y R7 es hidrogeno, alquilo C1-12, alquenilo C2-12, cicloalquilC3-8alquiloC1-4, alcanoilo C2-6, fenilalquilo C0-6, (heterociclo de 4 a 7 miembros)alquilo C0-6 o un grupo que está unido a L para formar un heterociclo de 4 a7 miembros; en donde cada uno de ii) y iii) está opcionalmente sustituido con desde 0 a 4 sustituyentes independientemente elegidos entre: a) halogeno, hidroxi, amino, ciano, nitro, -COOH, aminosulfonilo, aminocarbonilo y oxo; y b) alquilo C1-6, cicloalquilC3-8alquiloC0-2, haloalquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxiC1-6-carbonilo, alcanoilC2-6-amino, mono- y di-(alquilC1-6)aminoalquiloC0-4, alquilC1-6sulfonilo, mono- y di-(alquil C1-6)aminosulfonilo, mono- y di- (alquilC1-6)aminocarbonilalquiloC0-4, fenilalquilo C0-4 y (heterociclo de 4 a 7 miembros)alquiloC0-4, cada uno de los cuales está sustituido con desde 0 a 4 sustituyentes secundarios independientemente elegidos entre halogeno, hidroxi, ciano, oxo, imino, alquilo C1-4, alcoxi C1-4 y haloalquilo C1-4; y R4 representa desde 0 a 2 sustituyentes elegidos independientemente entre alquilo C1-3, haloalquilo C1-3 y oxo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60172104P | 2004-08-13 | 2004-08-13 | |
US64179605P | 2005-01-05 | 2005-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050194A1 true AR050194A1 (es) | 2006-10-04 |
Family
ID=36000525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103213A AR050194A1 (es) | 2004-08-13 | 2005-08-02 | Analogos de biaril piperazinil-piridina sustituidos |
Country Status (24)
Country | Link |
---|---|
US (2) | US7662830B2 (es) |
EP (1) | EP1786800B1 (es) |
JP (1) | JP4955554B2 (es) |
KR (1) | KR20070046924A (es) |
CN (1) | CN101014587B (es) |
AR (1) | AR050194A1 (es) |
BR (1) | BRPI0514319A (es) |
CA (1) | CA2577301C (es) |
CR (1) | CR8992A (es) |
EC (1) | ECSP077318A (es) |
HN (1) | HN2007006799A (es) |
IL (1) | IL181040A0 (es) |
MA (1) | MA28857B1 (es) |
MX (1) | MX2007001696A (es) |
MY (1) | MY145822A (es) |
NI (1) | NI200700040A (es) |
NO (1) | NO20071243L (es) |
NZ (1) | NZ553388A (es) |
PE (1) | PE20060620A1 (es) |
RU (1) | RU2413726C2 (es) |
SG (1) | SG157399A1 (es) |
TW (1) | TW200605889A (es) |
WO (1) | WO2006026135A2 (es) |
ZA (1) | ZA200701530B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030176437A1 (en) | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
JP2007534624A (ja) * | 2003-07-16 | 2007-11-29 | ニューロジェン・コーポレーション | ビアリールピペラジニル−ピリジン類縁体 |
MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
JP2008518955A (ja) | 2004-11-02 | 2008-06-05 | ノースウェスタン ユニバーシティ | ピリダジン化合物および方法 |
ES2543813T3 (es) | 2004-11-02 | 2015-08-24 | Northwestern University | Compuestos de piridazina para el tratamiento de enfermedades inflamatorias |
CN101080228A (zh) * | 2004-12-13 | 2007-11-28 | 神经能质公司 | 哌嗪基-吡啶类似物 |
AU2006206246A1 (en) * | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
JP2009535344A (ja) | 2006-04-28 | 2009-10-01 | ノースウェスタン ユニバーシティ | 神経炎症性疾患の処置のためのピリダジン化合物を含む処方物 |
US8158627B2 (en) | 2006-04-28 | 2012-04-17 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
WO2008057300A2 (en) * | 2006-10-27 | 2008-05-15 | Redpoint Bio Corporation | Trpvi antagonists and uses thereof |
EP2604599A1 (en) * | 2007-04-27 | 2013-06-19 | Purdue Pharma LP | TRPV1 antagonists and uses thereof |
US8343966B2 (en) * | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
JP2014511395A (ja) * | 2011-03-09 | 2014-05-15 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Pi3キナーゼインヒビターおよびその使用 |
ES2390326B1 (es) * | 2011-04-05 | 2013-08-14 | Universidad Miguel Hernández De Elche | Antagonistas de trpv1 y sus usos. |
JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体idhの阻害剤としての3−ピリミジン−4−イル−オキサゾリジン−2−オン類 |
JP6129199B2 (ja) * | 2011-12-02 | 2017-05-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピペリジン誘導体、その医薬組成物及び使用 |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
SG11201507063YA (en) | 2013-03-14 | 2015-10-29 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
CA2914762C (en) | 2013-07-30 | 2021-11-23 | Janssen Sciences Ireland Uc | Substituted pyridine-piperazinyl analogues as rsv antiviral compounds |
CN115060832B (zh) * | 2022-08-18 | 2022-11-29 | 上海奥科达生物医药科技有限公司 | 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4921148B1 (es) * | 1970-12-28 | 1974-05-30 | ||
US3775326A (en) | 1972-04-17 | 1973-11-27 | Addressograph Multigraph | Pressure fixable electroscopic printing powder |
FR2262512A1 (en) | 1974-03-01 | 1975-09-26 | Synthelabo | 2,4,6-Tri-substd. -1,3,5-triazines - with analgesic and psychotropic activity |
DE2643753A1 (de) | 1976-09-29 | 1978-04-06 | Thomae Gmbh Dr K | Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine |
FI70411C (fi) * | 1980-12-29 | 1986-09-19 | Pfizer | Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat |
DE3609596A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
US5589477A (en) | 1990-08-31 | 1996-12-31 | Nippon Shinyaku Company, Limited | Pyrimidine derivatives and drugs |
RU2147233C1 (ru) | 1994-08-08 | 2000-04-10 | Ниппон Синяку Ко., Лтд. | Лекарственные композиции и производные триазина |
US5962453A (en) | 1995-08-08 | 1999-10-05 | Nippon Shinyaku Co. Ltd. | Triazine derivative and medicine |
AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | グリコーゲンシンターゼキナーゼ3のインヒビター |
DE19836697A1 (de) | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
EP1185275A1 (en) | 1999-04-01 | 2002-03-13 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
WO2001070728A1 (en) * | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-[nitrogen-heterocyclic]pyrimidone derivatives |
EP1136483A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidone derivatives |
WO2002002539A1 (en) * | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
AU8066701A (en) | 2000-07-20 | 2002-02-05 | Neurogen Corp | Capsaicin receptor ligands |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
DE60234338D1 (de) | 2001-06-01 | 2009-12-24 | Hoffmann La Roche | Pyrimidin, triazin und pyrazinderivate als glutamatrezeptoren |
AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
KR101052482B1 (ko) | 2002-11-21 | 2011-07-28 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 포스포티딜이노시톨(pi) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용 |
CA2531401A1 (en) | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
JP2007534624A (ja) * | 2003-07-16 | 2007-11-29 | ニューロジェン・コーポレーション | ビアリールピペラジニル−ピリジン類縁体 |
WO2005009980A1 (en) | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
CN101080228A (zh) | 2004-12-13 | 2007-11-28 | 神经能质公司 | 哌嗪基-吡啶类似物 |
AU2006206246A1 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
US8258143B2 (en) * | 2006-06-28 | 2012-09-04 | Duquesne University Of The Holy Ghost | Methods of using substituted pyrrolo[2,3-d]pyrimidines for targeting tumor cells and treating cancer |
-
2005
- 2005-06-22 MY MYPI20052848A patent/MY145822A/en unknown
- 2005-07-01 TW TW094122269A patent/TW200605889A/zh unknown
- 2005-08-02 AR ARP050103213A patent/AR050194A1/es unknown
- 2005-08-11 PE PE2005000929A patent/PE20060620A1/es not_active Application Discontinuation
- 2005-08-13 MX MX2007001696A patent/MX2007001696A/es not_active Application Discontinuation
- 2005-08-13 CN CN2005800275501A patent/CN101014587B/zh not_active Expired - Fee Related
- 2005-08-13 KR KR1020077005831A patent/KR20070046924A/ko not_active Application Discontinuation
- 2005-08-13 WO PCT/US2005/028969 patent/WO2006026135A2/en active Application Filing
- 2005-08-13 CA CA2577301A patent/CA2577301C/en not_active Expired - Fee Related
- 2005-08-13 US US11/204,202 patent/US7662830B2/en active Active
- 2005-08-13 ZA ZA200701530A patent/ZA200701530B/xx unknown
- 2005-08-13 RU RU2007106042/04A patent/RU2413726C2/ru not_active IP Right Cessation
- 2005-08-13 EP EP05810146.0A patent/EP1786800B1/en active Active
- 2005-08-13 BR BRPI0514319-5A patent/BRPI0514319A/pt not_active IP Right Cessation
- 2005-08-13 NZ NZ553388A patent/NZ553388A/en unknown
- 2005-08-13 JP JP2007525874A patent/JP4955554B2/ja not_active Expired - Fee Related
- 2005-08-13 SG SG200907610-0A patent/SG157399A1/en unknown
-
2007
- 2007-01-29 IL IL181040A patent/IL181040A0/en unknown
- 2007-02-09 NI NI200700040A patent/NI200700040A/es unknown
- 2007-02-23 HN HN2007006799A patent/HN2007006799A/es unknown
- 2007-03-07 NO NO20071243A patent/NO20071243L/no not_active Application Discontinuation
- 2007-03-13 EC EC2007007318A patent/ECSP077318A/es unknown
- 2007-03-13 MA MA29749A patent/MA28857B1/fr unknown
- 2007-03-13 CR CR8992A patent/CR8992A/es not_active Application Discontinuation
-
2010
- 2010-02-15 US US12/705,964 patent/US8334382B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050194A1 (es) | Analogos de biaril piperazinil-piridina sustituidos | |
AR053712A1 (es) | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) | |
CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
AR063311A1 (es) | Compuestos organicos | |
AR054130A1 (es) | Procedimiento para la preparacion de 1-alquil-3-feniluracilos | |
CO5601012A2 (es) | Compuestos que modulan la actividad de ppar | |
PE20090509A1 (es) | El uso de derivados de benzamida para el tratamiento de transtornos del snc | |
AR023060A1 (es) | Uso de un compuesto que es un derivado de 2-ureido-1,3-tiazol, nuevos derivados de 2-ureido-1,3-tiazol, procedimientos para prepararlos y composicionesfarmaceuticas que los comprenden | |
AR063335A1 (es) | Derivados de 4- (2- amino-1- hidroxietil) fenol como agonistas del receptor beta 2 adrenergico | |
AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
AR073348A1 (es) | Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1 | |
AR073530A1 (es) | Inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos. inserto oftalmico | |
AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
AR043014A1 (es) | Amino-1,3,5-triazinas n-sustituidas con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas, y su uso como herbicidas y reguladores del crecimiento de las plantas | |
AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
AR054783A1 (es) | Derivados de pirrolo-quinolinas moduladores selectivos de receptores de androgeno | |
AR030243A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral | |
AR040333A1 (es) | Uso de derivados de ciclotiocarbamatos en el tratamiento de condiciones relacionadas con hormonas | |
AR060268A1 (es) | Tiazolil - dihidro - indazoles | |
CO6351734A2 (es) | Compuestos de amida utiles en terapia | |
AR060267A1 (es) | Tiazolil- dihidro -ciclopentapirazoles | |
AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |